Early Access

Back to AMGN

AMGEN INC Cash & Equivalents 2006-2025 | AMGN

Beta

What is cash & equivalents?

Cash and cash equivalents can be defined as the most liquid assets on a company's balance sheet, including cash on hand and short-term investments maturing within 90 days.

What is AMGEN INC's current cash & equivalents?

AMGEN INC (AMGN) annual cash & equivalents for 2025 was $9.13B, a 23.75% decline from 2024. AMGEN INC cash & equivalents for the quarter ending December 31, 2025 was $9.13B.

What was AMGEN INC's cash & equivalents in 2024?

AMGEN INC annual cash & equivalents for 2024 was $11.97B, a 9.40% increase from 2023.

What was AMGEN INC's cash & equivalents in 2023?

AMGEN INC annual cash & equivalents for 2023 was $10.94B, a 43.45% increase from 2022.

What is AMGEN INC's 5-year cash & equivalents CAGR?

AMGEN INC cash & equivalents grew at a compound annual growth rate (CAGR) of 7.82% from FY2020 to FY2025, going from $6.27B to $9.13B over 5 years.

Cash & Equivalents History

Year-over-year comparison from 10-K annual reports

Key Statistics
Trend Direction
Stable
CAGR+7.8%
FY2020
$6.27B
→
FY2025
$9.13B
0607080910111213141516171819202122232425
5 years selected
Cash & Equivalents History
PeriodValueChangeSource
FY2025$9.13B-23.8%10-K
FY2024$11.97B+9.4%10-K
FY2023$10.94B+43.5%10-K
FY2022$7.63B-4.5%10-K
FY2021$7.99B+27.5%10-K
FY2020$6.27B+3.8%10-K
FY2019$6.04B-13.1%10-K
FY2018$6.95B+82.8%10-K
FY2017$3.80B+17.2%10-K
FY2016$3.24B-21.8%10-K
FY2015$4.14B+11.1%10-K
FY2014$3.73B-1.9%10-K
FY2013$3.81B+16.8%10-K
FY2012$3.26B-53.1%10-K
FY2011$6.95B+111.3%10-K
FY2010$3.29B+14.0%10-K
FY2009$2.88B+62.6%10-K
FY2008$1.77B-12.4%10-K
FY2007$2.02B+57.8%10-K
FY2006$1.28B-10-K
Company: AMGEN INCTicker: AMGNSector: HealthcareIndustry: Biological Products, (No Diagnostic Substances)View company profile →